Neuropeptide

PE-22-28

PE-22-28 is a 7-amino-acid peptide that blocked the TREK-1 channel with an IC50 of 0.12 nM in cells and shortened immobility in mice; no human trial was identified.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

PE-22-28 after one dose: 50% at ~0.4 h, 25% at 0.8 h, 12.5% at 1.2 h.

Drawn from the half-life in the app's model, ~0.4 h. The model's figures

1

Overview

PE-22-28 was designed by Djillani and colleagues at the Institut de Pharmacologie Moléculaire et Cellulaire (CNRS, Université Côte d'Azur) and reported in Frontiers in Pharmacology in 2017.1 Its parent, spadin (PE 12-28), derives from a 44-amino-acid propeptide released when sortilin matures.1,2 The app's notes describe PE-22-28 as a fragment derived from DSIP; the 2017 paper traces it to spadin and its text does not mention DSIP.1 The app grades the evidence as emerging.1 The work described here was done in cells and mice.1

The 2017 paper reports that PE 22-28 "displayed a better specificity and affinity for TREK-1 channel compared to spadin, IC50 of 0.12 nM vs. 40-60 nM for spadin", measured by patch-clamp in a human TREK-1 cell line.1 The Figure 3 legend of the same paper gives IC50 values of 0.1 nM for PE 22-28 and 0.12 nM for G/A-PE 22-28, while the paper's summary and the results text give 0.12 nM for PE 22-28.1 Among the shortened peptides tested at 100 nM on arachidonic-acid-activated TREK-1 current, PE 22-27 and PE 22-25 had no significant effect, spadin inhibited 44.37 ± 8.817% (n = 7 cells) and PE 22-28 blocked 55.46 ± 4.6% (n = 13 cells).1 In cells transfected with other channels, PE 22-28 did not change TREK-2, TRAAK, TRESK or TASK-1 currents, and spadin analogs at 10 μM did not modify the hERG current.1 The authors write that spadin and its analogs "block TREK-1 channels more efficiently when they are activated by arachidonic acid".1

Deeper analysis: Djillani and colleagues, Frontiers in Pharmacology, 2017

The study combined cell electrophysiology with mouse behavioural tests: 30 min after an acute intraperitoneal dose of 3.0 to 4.0 μg/kg given across the three spadin analogs, PE 22-28 reduced forced-swim immobility to 91.80 ± 6.1 s (n = 10) against 161.7 ± 6.49 s with saline, and spadin at 100 μg/kg gave 88.3 ± 7.0 s in Table 1.1 In the corticosterone-induced model of depression, after 4 days of treatment latency to eat in the novelty suppressed feeding test was 153.2 ± 5.41 s with PE 22-28 (3 μg/kg) and 129.2 ± 15.28 s with spadin (100 μg/kg), against 226.1 ± 34.97 s in controls (n = 10 each); in mice given 3.0 to 4.0 μg/kg/day intraperitoneally for 4 days, BrdU-positive hippocampal cells numbered 1736 ± 126 with PE 22-28 against 899 ± 109 with saline (n = 5 each).1 The authors report that analogs "were also efficient after gavage" at 1 mg/kg in the forced swim test.1 The duration experiment used two analogs, not PE 22-28 itself: half-effect times were 14, 17, 21 and 23 h for G/A-PE 22-28 and biotinylated-G/A-PE 22-28 at the doses given, against 6 h for spadin in earlier work, and the paper's summary reports an action duration "up to 23 h instead of 7 h".1 Funding came from the Centre National de la Recherche Scientifique and the Agence Nationale de la Recherche (ANR grants), with the LabEx ICST and the Fondation de l'Avenir also named and one author supported by a CIFRE fellowship; the authors state that the research was conducted "in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest".1 The text read has no section on limitations; the authors write that they "could expect that spadin analogs would be devoid of side effects", an expectation drawn from channel selectivity and not a measured adverse-event result.1

Later papers from overlapping authors use the name mini-spadin, called spadin's "short analog" in the 2019 paper: in a mouse model of focal ischemia, daily intraperitoneal injections of 0.03 μg/kg and then 3 μg/kg were studied, and the 2021 paper on pancreatic beta-cells reports that "Mini-Spadin promotes beta-cell proliferation".3,4 Whether mini-spadin is the same peptide as PE 22-28 is not stated in the text of those two records, so their results are not attributed to PE-22-28 here.3,4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.4 h
Bioavailability
60%
Typical dose
100–500 mcg/day
Route
Nasal, SubQ
Time to peak
~0.25 h

Sources in this part

  1. 1Djillani et al., 2017
Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~0.4 h (the app's notes: about 20–30 minutes)The 2017 paper gives no number for a serum or plasma half-life of PE 22-28; it says the in vivo effect lasted almost 24 h "despite a relatively short in vitro serum half-life time"1
Duration of activity~2 h (the app's figure)Half-effect times of 14 to 23 h after a single injection of G/A-PE 22-28 or biotinylated-G/A-PE 22-28 at 3.2 to 40 μg/kg (10 mice per time point), against 6 h for spadin at 100 μg/kg in earlier work; PE 22-28 itself was not in this experiment, and the paper's summary figure of "up to 23 h instead of 7 h" refers to PE 22-28 and its analogs1
Bioavailability60% (the app's figure)No bioavailability figure appears in the 2017 paper1
Time to peak~0.25 h (the app's figure)No time to peak appears in the 2017 paper; effects were tested at 30 min and at 1, 3, 5, 7, 12, 16, 20 and 24 h1
RouteNasal, SubQ (the app's figure)Intraperitoneal injection and gavage in mice; nasal and subcutaneous routes are not described in the 2017 paper1

The half-effect times above are durations of behavioural effect in the forced swim test, a pharmacodynamic measure, and are not plasma half-lives.1

4

Regulatory and anti-doping status

The 2026 WADA Prohibited List does not name PE-22-28; its S0 class covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", including drugs under pre-clinical development.5 No DailyMed label for PE-22-28 was identified.

5

What is not known

Sources in this part

  1. 1Djillani et al., 2017

No controlled trial in people was identified in PubMed or ClinicalTrials.gov, so no human efficacy, safety or pharmacokinetic result was identified in those records. The paper's own measurements are limited to cell recordings and male mice 7 to 9 weeks old, with PE 22-28 groups of 5 to 13 cells or mice.1 The app's half-life, bioavailability, time to peak, nasal and subcutaneous routes and 100–500 mcg/day range have no matching figure in the sources read.

What is PE-22-28?

PE-22-28 is a 7-amino-acid peptide designed from spadin's blood degradation products.1

What is the half-life of PE-22-28?

The app lists about 0.4 hours (roughly 24 minutes), and the 2017 paper gives no numeric plasma half-life for PE 22-28.1 In mice, the half-effect time on forced-swim immobility after a single injection was 14 to 23 h for G/A-PE 22-28 and biotinylated-G/A-PE 22-28 at 3.2 to 40 μg/kg, against 6 h for spadin at 100 μg/kg in earlier work; PE 22-28 itself was not in this experiment.1

Is PE-22-28 banned by WADA?

The 2026 Prohibited List does not name PE-22-28.5 Its S0 class prohibits at all times any pharmacological substance that is not addressed by the subsequent sections of the List and has no current approval by any governmental regulatory health authority for human therapeutic use.5

Has PE-22-28 been tested in humans?

No human trial of PE-22-28 was identified in PubMed or ClinicalTrials.gov.

What does PE-22-28 target?

PE-22-28 blocks the TREK-1 potassium channel in a human TREK-1 cell line, with an IC50 of 0.12 nM.1

Is PE-22-28 derived from DSIP?

The 2017 paper describes PE-22-28 as derived from spadin, not from DSIP, while the app's notes say DSIP.1

Is PE-22-28 the same as mini-spadin?

The text of the Pietri 2019 and Daziano 2021 records does not state that mini-spadin is PE 22-28.3,4

8

References

  1. Djillani A, et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol 2017;8:643. PMID 28955242
  2. Mazella J, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol 2010;8(4):e1000355. PMID 20405001
  3. Pietri M, et al. First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology 2019;158:107715. PMID 31325429
  4. Daziano G, et al. Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway. Pharmacol Res 2021;167:105539. PMID 33737242
  5. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list